Who is sponsoring NCT04637724?

NCT04637724 is sponsored by Oded Meiron.

What drugs are being tested in NCT04637724?

Interventions in NCT04637724: transcranial direct current stimulation (tDCS).

What condition does NCT04637724 study?

NCT04637724 studies Schizophrenia, Schizo Affective Disorder.

Is NCT04637724 still recruiting?

NCT04637724 is currently completed. Last updated 25 September 2023.

Last reviewed 2023-09-25 · How we verify

NCT04637724

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transcranial Weak Current Stimulation Treatments for Working Memory Dysfunction in Schizophrenia

Completed NA Last updated 25 September 2023

What this trial tests

NA trial testing transcranial direct current stimulation (tDCS) in Schizophrenia in 33 participants. Completed in 10 September 2023.

Timeline

29 November 2019

Primary endpoint
30 August 2023

10 September 2023

Quick facts

Lead sponsor	Oded Meiron
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	33
Start date	29 November 2019
Primary completion	30 August 2023
Estimated completion	10 September 2023
Sites	1 location across Israel

Drugs / interventions tested

transcranial direct current stimulation (tDCS)

Conditions studied

Schizophrenia — all drugs for Schizophrenia →
Schizo Affective Disorder — all drugs for Schizo Affective Disorder →

Sponsor

Oded Meiron

Who can join

Adults 18 to 75, any sex, with Schizophrenia or Schizo Affective Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

For the present study, Investigators will examine the efficacy of active prefrontal anodal tDCS versus placebo (sham) interventions to treat WM dysfunction in schizophrenia. Investigators selected the prefrontal stimulation modality that proved most effective in enhancing high-load WM performance in single dose stimulation in healthy participants . The study employs a multi-stimulation approach, with 2 sessions per day for 5 consecutive days in the active treatment group (n=15) compared to a group that receives only sham stimulation (n=15). This preliminary approach is based upon findings of a recent study applying cathodal tDCS stimulation over left temporoparietal cortex (with left prefrontal anodal stimulation) for the treatment of persistent auditory hallucinations in schizophrenia. In a a recent study clinical benefits were maintained for at least 3 months following stimulation. In the present study, in addition to clinical outcome, researchers will evaluate whether similar improvement can be obtained with WM, EEG activity, and functional outcome (e.g., discharged from hospitalization following significant improvement or remission).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Transcranial direct-current stimulation of the prefrontal cortex enhances working memory and suppresses pathological gamma power elevation in schizophrenia.
Meiron O, Yaniv A, Rozenberg S, David J. · · 2024 · cited 2× · PMID 38084398 · DOI 10.1080/14737175.2023.2294150

Verify or expand the search:

Other trials of transcranial direct current stimulation (tDCS)

Trials testing the same drug.

NCT07535788 — Implementing Transcranial Direct Current Stimulation in a Rehabilitation Setting · not yet recruiting
NCT07458503 — tDCS Combined With Constraint-Induced Therapy in Post-Stroke Upper Limb Rehabilitation · NA · not yet recruiting
NCT07500064 — Transcranial Direct Current Stimulation for Depression · NA · not yet recruiting
NCT07228468 — Home-Based Transcranial Direct Current Stimulation In Major Depressive Disorder (HOME) · NA · recruiting
NCT06883266 — Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD · NA · recruiting

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other Oded Meiron trials

Trials by the same sponsor.

NCT04614792 — Excitatory Prefrontal Weak Current Stimulation in Vegetative Patients · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04637724 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oded Meiron
Last refreshed: 25 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04637724.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing